优化治疗介于IL-1的自身炎症性疾病:基于疾病活动的治疗调整的影响
Tatjana Welzel1,2,3, Beate Zapf3, Jens Klotsche4
1Pediatric Rheumatology, University Children's Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Journal of clinical medicine
|April 27, 2024
概括
对IL-1自发炎性疾病 (IL-1 AID) 的有效治疗调整显著改善了儿童的疾病控制. 这项研究强调了基于疾病活动的个性化策略的好处,以改善患者的治疗结果.
科学领域:
- 儿科风湿病学 儿科风湿病学
- 自燃性炎症疾病 自燃性炎症疾病
- 遗传学 是一个遗传学.
背景情况:
- 介素-1自身炎症性疾病 (IL-1 AID) 需要有效的疾病控制来预防长期损伤.
- 对现实世界治疗调整的纵向分析对于优化IL-1 AID的护理至关重要.
- 目前的治疗策略旨在控制疾病活动并改善患者的治疗结果.
研究的目的:
- 纵向分析基于疾病活动的协议化治疗调整在IL-1 AID儿童的现实生活队列中的影响.
- 评估量身定制的治疗策略在管理疾病活动和改善患者治疗结果方面的有效性.
- 确定影响儿科IL-1 AID疾病活动轨迹的因素.
主要方法:
- 一个单中心研究包括连续的儿童,在2016年1月至2019年12月期间被诊断患有IL-1 AID.
- 收集的数据包括人口统计,表型,基因型,炎症标志物和医生/患者全球评估 (PGA/PPGA).
- 评估了疾病活动和治疗变化,并分析了它们对疾病轨迹的影响.
主要成果:
- 包括56名儿童,随访时间中位数为2.1年.
- 在基线时,68%的患者有中度至重度的疾病活动;50%需要治疗调整.
- 在最后的随访中,79%的患者实现了良好的疾病控制,PGA和PPGA显著下降.
结论:
- 基于疾病活动的治疗调整有效地改进了IL-1 AID的治疗到目标策略.
- 由疾病活动指导的个性化精确健康方法改善了儿科IL-1 AID的结果.
- 协议化治疗调整对于优化长期管理和预防IL-1 AID儿童损伤至关重要.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
134
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
134
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
160
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
160
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138


